Milestone indicates intraoperative radiation therapy (IORT) with electrons is gaining momentum as a treatment option for women with breast cancer
SUNNYVALE, Calif. – IntraOp Medical Corporation today announced that more than 7,500 women with breast cancer have been treated with the IntraOp® Mobetron®, an intraoperative radiation therapy (IORT) device used to deliver a precise, cancer-killing dose of electrons in the operating room during surgery when residual microscopic tumor cells are exposed and most vulnerable. Two minutes of treatment with the Mobetron can replace six weeks of conventional, post-operative external beam x-ray radiation. For women with breast cancer, that means faster treatment and recovery with fewer side effects.
“The Mobetron has been used by leading hospitals and surgical centers to treat many types of cancer during the last 20 years. However, breast cancer is the fastest-growing indication among our users today, with more than 7,500 cases treated worldwide. We expect that trend to continue and to gain momentum with the recent publications such as the GEC-ESTRO trial demonstrating level one evidence of the equivalence of accelerated partial breast irradiation (APBI) to whole breast irradiation (WBI) in select patients,” said IntraOp CEO Bruce Khouri. “Significantly, the unique compatibility of the Mobetron with modern oncoplastic breast reconstruction, coupled with patients’ increasing desire for shorter treatment times will be additive to this trend,” noted Khouri.
The Mobetron is currently utilized by notable cancer centers, clinics and teaching hospitals in the United States such as the Mayo Clinic, University of North Carolina, Ohio State University, Stanford University Medical Center, Scripps, and many other leading institutions in Europe, Asia and the Middle East.
The speed, mobility, and versatility of the Mobetron makes it an indispensable treatment modality for major breast cancer centers committed to developing an effective and comprehensive IORT program…
“The speed, mobility, and versatility of the Mobetron makes it an indispensable treatment modality for major breast cancer centers committed to developing an effective and comprehensive IORT program,” said Derek DeScioli, IntraOp Vice President of Global Sales. “Whether used as a boost for improved local control and cosmetic results, or as a two-minute, single-fraction APBI treatment, we are seeing higher utilization and adoption throughout the world. That 7,500 breast cancer patients have been treated with the Mobetron is a major milestone for IntraOp and the future of cancer care,” added DeScioli.